Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon

About this trial

Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity.

Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.

Eligibility criteria

Qualifiers

Age > 18 years

chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)

ability to perform questionnaires

Disqualifiers

Judicial protection measure

Refusal to participate in the study

Suffering from 2 rheumatic disease simultaneously

Trial design

Treatments tested in this trial

  • Dietary Questionnaire
  • Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)

Treatment groups

240 Participants
are divided into 4 treatment groups

Sponsors and collaborators